Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Second Line Chemo or Tarceva: Which is Better for Advanced NSCLC Patients without an EGFR Mutation?
Author
Howard (Jack) West, MD

Dr. Mark Socinski covered the TAILOR trial, an Italian study directly comparing second line Taxotere (docetaxel) to Tarceva (erlotinib) in advanced NSCLC patients without an EGFR mutation, in the ASCO Lung Cancer Highlights program.  However, as a preview to his comments you'll find in the podcast here, I'll share that he wasn't fond of the trial or the questionable value of the results from it.  

Still, the trial is among the ones likely to be most discussed in the field of lung cancer from ASCO 2012, so it's worth hearing what it showed, along with an expert perspective of how to interpret it.  Below, you'll find the audio and video versions of the podcast along with the transcript and figures.

Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Audio Podcast

Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Transcript

Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Figs

We'll finish Dr. Socinski's presentation of ASCO Highlights in Lung Cancer with his summary of some work in small cell lung cancer. Look for that soon.

 

 

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.